Hospital course
| Indicators of organ dysfunction | |
| Creatin—mg/dL (median±SD) | 3.7±3.9 |
| Kidney injury (Cre >2.0, n, %) | 68 (65%) |
| ALT—units/L (median±SD) | 29±861 |
| AST—units/L (median±SD) | 52±1097 |
| Hepatic injury (LFTs>100, n, %) | 29 (28%) |
| Troponin—ng/L (median±SD) | 65±2760 |
| Cardiac injury (trop >100, n, %) | 32 (31%) |
| PT—s (median±SD) | 12.0±14.9 |
| INR (median±SD) | 1.17±1.64 |
| Coagulation dysfunction (INR >2, n, %) | 11 (11%) |
| Cultures | |
| Positive blood cultures (n, %) | 14 (13.5%) |
| Not obtained (n, %) | 9 (8.7%) |
| Positive respiratory cultures (n, %) | 26 (25.0%) |
| Not obtained (n, %) | 47 (45.2%) |
| Staphylococcus aureus (n, %) | 3 (2.9%) |
| Pseudomonas aeruginosa (n, %) | 7 (6.7%) |
| Treatments received | |
| Hydroxychloroquine (n, %) | 82 (78.8%) |
| Steroids (n, %) | 76 (73.1%) |
| IL-6 inhibitor (n, %) | 5 (4.8%) |
| Convalescent plasma (n, %) | 0 (0%) |
| ECMO (n, %) | 4 (3.8%) |
| Anticoagulation | |
| DVT prophylaxis dosing (n, %) | 45 (43.3%) |
| Therapeutic (n, %) | 47 (45.2%) |
| None (n, %) | 12 (11.5%) |
| Outcomes | |
| Hospital length of stay (days, median±SD) | 16±15.6 |
| ICU admission (n, %) | 79 (76.0%) |
| ICU length of stay (days, median ±SD)* | 9.0±16.1 |
| Required intubation (n, %) | 62 (57.9%) |
| Length of intubation (days, median±SD)† | 8.0±10.8 |
| Ventilator free days at 28 days (median±SD) | 0.0±12.3 |
| Outcome at 60 days | |
| Discharged (n, %) | 38 (36.5%) |
| Remained inpatient (n, %) | 3 (2.9%) |
| Hospice (n, %) | 8 (7.7%) |
| Deceased (n, %) | 55 (52.8%) |
| Readmission within 30 days (n, %) | 6 (5.7%) |
*Among individuals admitted to the ICU.
†Among individuals requiring intubation.
ALT, alanine transaminase; AST, aspartate transaminase; DVT, deep vein thrombosis; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; IL-6, interleukin 6; INR, international normalised ratio; LFT, liver function tests; PT, prothrombin time.